文献速递神经肿瘤

USP36通过去泛素化并稳定ALKBH5促进胶质母细胞瘤的发生及药物敏感性

USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
PubMed 文献 · Neuro Oncol · 2023-01-01

本研究探讨去泛素化酶对ALKBH5蛋白稳定性的调控机制。研究发现USP36作为ALKBH5的去泛素化酶,可稳定ALKBH5并调控其介导的基因表达;敲低USP36可损害胶质母细胞瘤细胞增殖与胶质瘤干细胞自我更新,并使其对替莫唑胺敏感,同时在体内显著减少肿瘤生长。USP36-ALKBH5轴参与胶质瘤发生,USP36可能成为胶质母细胞瘤的潜在治疗靶点。

要点

  • USP36是ALKBH5的去泛素化酶,可稳定ALKBH5蛋白并调控其介导的基因表达。
  • 敲低USP36可损害胶质母细胞瘤细胞增殖、恶化胶质瘤干细胞自我更新,并使其对替莫唑胺敏感。
  • 敲除USP36在体内显著减少肿瘤生长,USP36-ALKBH5轴参与胶质瘤发生。

核心结论

  • USP36是ALKBH5的去泛素化酶,在胶质母细胞瘤进展中发挥作用,可能作为胶质母细胞瘤治疗的潜在靶点。

研究设计与样本

  • 研究采用蛋白质印迹分析全面分析去泛素化酶对ALKBH5蛋白表达波动的影响,并用质谱和免疫沉淀鉴定USP36与ALKBH5的相互作用。
  • 研究通过体内和体外泛素化实验检测USP36对ALKBH5稳定性的影响,并采用细胞增殖实验、神经球形成实验、有限稀释实验和颅内肿瘤生长实验评估USP36与ALKBH5在肿瘤发生中的协同能力。

主要发现

  • ubiquitin-specific peptidase 36(USP36)作为潜在的ALKBH5激活去泛素化酶,在稳定ALKBH5和调控ALKBH5介导的基因表达中发挥重要作用。
  • 敲低USP36大幅损害细胞增殖、恶化胶质瘤干细胞的自我更新,并使胶质瘤干细胞对替莫唑胺(TMZ)治疗敏感。
  • 敲除USP36在生物发光成像监测下大幅减少体内肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ALKBH5 is aberrantly activated and exerts critical roles in facilitating the development of glioblastoma. However, the underlying activation mechanism by which ALKBH5 protein is increased in glioblastoma is not completely understood. Our study aimed to elucidate the signaling pathways involved in mediating ALKBH5 protein stability. METHODS: The contribution of deubiquitinating enzymes (DUB) to the fluctuation of ALKBH5 protein expression was globally profiled with western blot analysis. Mass spectrometry and immunoprecipitation were performed to identify the USP36 and ALKBH5 interaction. The effects of USP36 on the stability of ALKBH5 were detected with in vivo and in vitro ubiquitination assays. Cell proliferation assays, neurosphere formation, limited dilution assay, and intracranial tumor growth assays were implemented to assess the collaborative capacities of USP36 and ALKBH5 in tumorigenesis. RESULTS: Ubiquitin-specific peptidase 36 (USP36), as a potential ALKBH5-activating DUB, played an essential role in stabilization of ALKBH5 and regulation of ALKBH5-mediated gene expression in glioblastoma. The depletion of USP36 drastically impaired cell proliferation deteriorated the self-renewal of GSCs and sensitized GSCs to temozolomide (TMZ) treatment. Furthermore, the deletion of USP36 substantially decreased the in vivo tumor growth when monitored by bioluminescence imaging. Our findings indicate that USP36 regulates the protein degradation and expression of ALKBH5, and the USP36-ALKBH5 axis orchestrates glioma tumorigenesis. CONCLUSION: Our findings identify USP36 as a DUB of ALKBH5 and its role in glioblastoma progression, which may serve as a potential therapeutic target for glioblastoma treatment.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Chang G, Xie GS, Ma L, et al. USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5. Neuro Oncol. 2023. PMID: 36239338. doi:10.1093/neuonc/noac238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。